ESTRO 2024 - Abstract Book

S1610

Clinical - Lung

ESTRO 2024

PCI in this cohort. Stage was the only independent parameter that impacted OS. This calls for prospective randomized trials (like ongoing NCT04155034 and NCT04790253) to determine if PCI does have an OS advantage in modern times.

Keywords: PCI, SCLC, limited disease

484

Proffered Paper

SAKK 16/18: QA and interim safety of immune-modulatory RT in resectable stage III(N2) NSCLC

Tobias Finazzi 1 , Lisa Holer 2 , Hongjian Tang 3 , Oliver Riesterer 4 , Abdelkarim Allal 5 , Olgun Elicin 6 , Markus Glatzer 7 , André Durham 8 , Francesco Martucci 9 , Lukas Adam 10 , Katarzyna Mosna-Firlejczyk 11 , Adrienne Bettini 12 , David König 13 , Simon Haefliger 14 , Martin Früh 15 , Wolf-Dieter Janthur 16 , Alfredo Addeo 17 , Patrizia Froesch 18 , Michael Mark 19 , Bernhard Scheibe 2 , Patrick Dorn 20 , Spasenija Savic Prince 21 , Sacha I. Rothschild 22 , Matthias Guckenberger 23 , Laetitia A. Mauti 24 1 University Hospital Basel, Clinic of Radiotherapy and Radiation Oncology, Basel, Switzerland. 2 Swiss Group for Clinical Cancer Research (SAKK), Competence Center, Bern, Switzerland. 3 Kantonsspital Winterthur, Department of Radiation Oncology, Winterthur, Switzerland. 4 Kantonsspital Aarau, Radiation Oncology Center KSA-KSB, Aarau, Switzerland. 5 HFR - Hôpital Fribourgeois, Department of Radiation Oncology, Fribourg, Switzerland. 6 Inselspital, Bern University Hospital, Department of Radiation Oncology, Bern, Switzerland. 7 Kantonsspital St. Gallen, Department of Radiation Oncology, St. Gallen, Switzerland. 8 University Hospital HUG, Department of Radiation Oncology, Geneva, Switzerland. 9 Oncology Institute of Southern Switzerland, Department of Radiation Oncology, Bellinzona, Switzerland. 10 Kantonsspital Graubünden, Department of Radiation Oncology, Chur, Switzerland. 11 St. Claraspital Basel, Department of Radiation Oncology, Basel, Switzerland. 12 HFR - Hôpital Fribourgeois, Department of Oncology, Fribourg, Switzerland. 13 University Hospital Basel, Department of Medical Oncology, Basel, Switzerland. 14 Inselspital, Bern University Hospital, Department of Medical Oncology, Bern, Switzerland. 15 Kantonsspital St. Gallen, Department of Oncology / Hematology, St. Gallen, Switzerland. 16 Kantonsspital Aarau, Department of Oncology / Hematology, Aarau, Switzerland. 17 University Hospital HUG, Department of Oncology, Geneva, Switzerland. 18 Oncology Institute of Southern Switzerland, Department of Medical Oncology, Bellinzona, Switzerland. 19 Kantonsspital Graubünden, Department of Oncology / Hematology, Chur, Switzerland. 20 Inselspital, Bern University Hospital, Department of Thoracic Surgery, Bern, Switzerland. 21 University Hospital Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland. 22 Kantonsspital Baden, Department of Oncology / Hematology, Baden, Switzerland. 23 University Hospital Zurich, Department of Radiation Oncology, Zurich, Switzerland. 24 Kantonsspital Winterthur, Department of Oncology, Winterthur, Switzerland

Purpose/Objective:

SAKK 16/18 (NCT04245514) is a prospective multicenter phase II trial exploring the use of immune-modulatory radiotherapy (RT) to enhance the effects of neoadjuvant PD-L1 blockade after chemotherapy in resectable stage